AR083208A1 - Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion - Google Patents

Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion

Info

Publication number
AR083208A1
AR083208A1 ARP110103586A ARP110103586A AR083208A1 AR 083208 A1 AR083208 A1 AR 083208A1 AR P110103586 A ARP110103586 A AR P110103586A AR P110103586 A ARP110103586 A AR P110103586A AR 083208 A1 AR083208 A1 AR 083208A1
Authority
AR
Argentina
Prior art keywords
inhalation
dry powder
powder formulations
magnesium estearate
hydrolysis
Prior art date
Application number
ARP110103586A
Other languages
English (en)
Inventor
Daniela Cocconi
Alberi Massimiliano Dagli
Andrea Busca
Francesca Schiaretti
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR083208A1 publication Critical patent/AR083208A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de estearato de magnesio en formulación en polvo para inhalación que comprende partículas de vehículo para inhibir o reducir la degradación química de un ingrediente activo que porta un grupo susceptible de hidrólisis. Una formulación farmacéutica en forma de polvo seco para inhalación que comprende (a) un vehículo, (b) estearato de magnesio, y c) una sustancia ingrediente activo susceptible de hidrólisis.
ARP110103586A 2010-09-30 2011-09-29 Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion AR083208A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10183018 2010-09-30

Publications (1)

Publication Number Publication Date
AR083208A1 true AR083208A1 (es) 2013-02-06

Family

ID=43618674

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103586A AR083208A1 (es) 2010-09-30 2011-09-29 Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion

Country Status (13)

Country Link
US (3) US20120082727A1 (es)
EP (1) EP2621494B1 (es)
KR (2) KR20140005150A (es)
CN (1) CN103298470B (es)
AR (1) AR083208A1 (es)
BR (1) BR112013007022B1 (es)
CA (1) CA2813096C (es)
ES (1) ES2704688T3 (es)
HK (1) HK1187822A1 (es)
PL (1) PL2621494T3 (es)
RU (1) RU2580890C2 (es)
TR (1) TR201901644T4 (es)
WO (1) WO2012041717A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
EP2762133A1 (en) 2010-04-01 2014-08-06 CHIESI FARMACEUTICI S.p.A. Process for preparing carrier particles for dry powders for inhalation
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
TWI586378B (zh) 2012-03-13 2017-06-11 瑞斯比維特有限公司 新穎醫藥調配物
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
WO2014106727A1 (en) * 2013-01-03 2014-07-10 Vectura Limited Inhaler and formulation
GB201305825D0 (en) * 2013-03-28 2013-05-15 Vectura Ltd New use
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CN110305095A (zh) * 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア
AU2017423862A1 (en) 2017-07-20 2020-02-06 Aztherapies, Inc. Powdered formulations of cromolyn sodium and ibuprofen
JP2021529771A (ja) 2018-07-02 2021-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリンナトリウムおよびα−ラクトースの粉末製剤
WO2023224577A1 (en) * 2022-05-18 2023-11-23 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising micronized human insulin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1131059B1 (de) * 1998-11-13 2003-03-05 Jago Research Ag Trockenpulver zur inhalation
CZ298489B6 (cs) 1999-03-05 2007-10-17 Chiesi Farmaceutici S. P. A. Prášek pro použití v inhalátoru
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
EP1386630B1 (en) 2002-07-31 2006-05-17 CHIESI FARMACEUTICI S.p.A. Powder inhaler
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
JP2009513529A (ja) 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
US7590021B2 (en) 2007-07-26 2009-09-15 Qualcomm Incorporated System and method to reduce dynamic RAM power consumption via the use of valid data indicators
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof

Also Published As

Publication number Publication date
HK1187822A1 (en) 2014-04-17
KR20140005150A (ko) 2014-01-14
KR20170118231A (ko) 2017-10-24
US20180133161A1 (en) 2018-05-17
BR112013007022A2 (pt) 2016-06-14
CN103298470B (zh) 2015-06-17
RU2013113965A (ru) 2014-10-10
CA2813096A1 (en) 2012-04-05
KR101886987B1 (ko) 2018-08-08
US20150320691A1 (en) 2015-11-12
TR201901644T4 (tr) 2019-02-21
RU2580890C2 (ru) 2016-04-10
CA2813096C (en) 2019-10-29
CN103298470A (zh) 2013-09-11
EP2621494A1 (en) 2013-08-07
ES2704688T3 (es) 2019-03-19
PL2621494T3 (pl) 2019-04-30
WO2012041717A1 (en) 2012-04-05
US20120082727A1 (en) 2012-04-05
EP2621494B1 (en) 2018-11-07
BR112013007022B1 (pt) 2019-10-15

Similar Documents

Publication Publication Date Title
AR083208A1 (es) Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
TR201900670T4 (tr) İnhalasyon için yöntem ve formülasyon.
CY1120684T1 (el) Σκευασμα ξηρης σκονης που περιλαμβανει ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης
PE20150668A1 (es) Formulaciones farmaceuticas topicas no acuosas
WO2013114371A8 (en) Dry powder formulations of dnase i
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
WO2010021607A3 (en) Pharmaceutical formulation
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
BR112013004829A2 (pt) composição de agente de dispersão de produto químico agrícola, composição química agrícola, método para produzir um produto agrícola, método para aumentar eficácia em um produto químico agrícola, e uso da composição de agente de dispersão de produto químico agrícola.
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
CO6640305A2 (es) Elaboración de gránulos sin activos y tabletas que comprenden los mismos
DOP2014000269A (es) Nueva dosificación y formulación
WO2013104892A8 (en) Application of high dose compounds via inhalation
CL2015001748A1 (es) Formulaciones antiparasitarias transdermicas
BR112013019924A2 (pt) composições para cuidado oral
PH12015500374A1 (en) Extended release compositions of an aminoalkyl nitrate
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
TR201009399A2 (tr) Hızlı çözünen efervesan rosuvastatin formülasyonları.
CL2012002924A1 (es) Una composicion que contiene como ingrediente activo a perclorato de 4-tioureido-iminometilpiridinio y sustancias farmaceuticamente aceptables; metodo de preparacion; y su uso para el tratamiento y/o la prevencion de todas las formas de tuberculosis pulmonar y extrapulmonar.
EP2968156A4 (en) Fine dry particulate resveratrol active agent compositions and topical formulations including the same

Legal Events

Date Code Title Description
FC Refusal